中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
16期
2479-2481,2482
,共4页
雷贝拉唑%四联疗法%螺杆菌,幽门%胃溃疡%白细胞介素18%白细胞介素35
雷貝拉唑%四聯療法%螺桿菌,幽門%胃潰瘍%白細胞介素18%白細胞介素35
뢰패랍서%사련요법%라간균,유문%위궤양%백세포개소18%백세포개소35
Leibeirazole%quadruple therapy%Helicobaer,pyloriterp%gastric ulcer%Interlenkin -18%Interlen-kin -18
目的:探讨雷贝拉唑为主的四联疗法治疗复发性幽门螺杆菌(Hp)阳性胃溃疡患者的疗效,观察其对血清白细胞介素18(IL-18)和白细胞介素35(IL-35)的影响。方法选择180例复发性 Hp 阳性的胃溃疡患者,应用随机数字表法将其分为两组,对照组(90例)应用胶体果胶铋、阿莫西林、克拉霉素进行治疗,观察组(90例)在上述基础上加用雷贝拉唑进行治疗。治疗4周行胃镜检查。同时检测治疗前、后血清中IL-18和 IL-35的表达。结果两组治疗后显效率(86.67%比73.33%,χ2=5.000,P =0.025)、炎性反应的阳性率(26.67%比51.11%,χ2=11.314,P =0.008)、Hp 阳性率(16.67%比31.11%,χ2=5.163,P =0.023)差异均有统计学意义。观察组治疗后血清中 IL-18的表达明显下降[(70.80±11.21)比(88.83±7.13),t =8.27,P =0.021],对照组无明显变化[(85.62±10.84)比(87.64±9.28),t =0.78,P =0.451]。两组治疗前后血清中 IL-35水平差异均无统计学意义(P >0.05)。结论以雷贝拉唑为主的四联疗法治疗复发性 Hp 阳性胃溃疡的疗效明显,且能有效下调血清中 IL-18的表达。
目的:探討雷貝拉唑為主的四聯療法治療複髮性幽門螺桿菌(Hp)暘性胃潰瘍患者的療效,觀察其對血清白細胞介素18(IL-18)和白細胞介素35(IL-35)的影響。方法選擇180例複髮性 Hp 暘性的胃潰瘍患者,應用隨機數字錶法將其分為兩組,對照組(90例)應用膠體果膠鉍、阿莫西林、剋拉黴素進行治療,觀察組(90例)在上述基礎上加用雷貝拉唑進行治療。治療4週行胃鏡檢查。同時檢測治療前、後血清中IL-18和 IL-35的錶達。結果兩組治療後顯效率(86.67%比73.33%,χ2=5.000,P =0.025)、炎性反應的暘性率(26.67%比51.11%,χ2=11.314,P =0.008)、Hp 暘性率(16.67%比31.11%,χ2=5.163,P =0.023)差異均有統計學意義。觀察組治療後血清中 IL-18的錶達明顯下降[(70.80±11.21)比(88.83±7.13),t =8.27,P =0.021],對照組無明顯變化[(85.62±10.84)比(87.64±9.28),t =0.78,P =0.451]。兩組治療前後血清中 IL-35水平差異均無統計學意義(P >0.05)。結論以雷貝拉唑為主的四聯療法治療複髮性 Hp 暘性胃潰瘍的療效明顯,且能有效下調血清中 IL-18的錶達。
목적:탐토뢰패랍서위주적사련요법치료복발성유문라간균(Hp)양성위궤양환자적료효,관찰기대혈청백세포개소18(IL-18)화백세포개소35(IL-35)적영향。방법선택180례복발성 Hp 양성적위궤양환자,응용수궤수자표법장기분위량조,대조조(90례)응용효체과효필、아막서림、극랍매소진행치료,관찰조(90례)재상술기출상가용뢰패랍서진행치료。치료4주행위경검사。동시검측치료전、후혈청중IL-18화 IL-35적표체。결과량조치료후현효솔(86.67%비73.33%,χ2=5.000,P =0.025)、염성반응적양성솔(26.67%비51.11%,χ2=11.314,P =0.008)、Hp 양성솔(16.67%비31.11%,χ2=5.163,P =0.023)차이균유통계학의의。관찰조치료후혈청중 IL-18적표체명현하강[(70.80±11.21)비(88.83±7.13),t =8.27,P =0.021],대조조무명현변화[(85.62±10.84)비(87.64±9.28),t =0.78,P =0.451]。량조치료전후혈청중 IL-35수평차이균무통계학의의(P >0.05)。결론이뢰패랍서위주적사련요법치료복발성 Hp 양성위궤양적료효명현,차능유효하조혈청중 IL-18적표체。
Objective To investigate the effect and changes of IL -18 and IL -35 in patients with recurrent Hp positive gastric ulcer by treating with leibeirazole quadruple therapy.Methods 180 patients with recurrent Hp positive gastric ulcer were divided into two groups.The control group(90 cases)was applied amoxicillin,clarithromy-cin and colloidal bismuth pectin.The observation group was added leibeirazole.The effect and changes of IL -18 and IL -35 were observed before and after treatment in the two groups.Results The effective rate (86.67% vs. 73.33%,χ2 =5.000,P =0.025),inflammatory reaction rate(26.67% vs.51.11%,χ2 =11.314,P =0.008)and Hp positive rate(16.67 % vs.31.11%,χ2 =5.163,P =0.023)were higher in the observation group than in the control group.Expression of IL -18 was decreased after treatment[(70.80 ±11.21)ng/L vs.(88.83 ±7.13)ng/L, t =8.27,P =0.0210]in the observation group,but no change in the control group[(85.62 ±10.84)ng/L vs. (87.64 ±9.28)ng/L,t =0.78,P =0.4512).Expression of IL -35 didn't change after treatment in the two group (P >0.05).Conclusion Leibeirazole quadruple can increase the clinical effect,decrease the expression of IL -18 in patients with recurrent Hp positive gastric ulcer,it is worthy to be applied in clinical treatment.